Frank Reynolds, President and CEO of InVivo Therapeutics describes the company’s strategy in bringing its unique spinal cord injury (SPI) products to market.
Arun Menawat Discusses Novadaq Technologies, a Surgical Imaging Company
Novadaq Technologies (TSX:NDQ) President & CEO Arun Menawat, Ph.D was interviewed by OneMedRadio and discusses the roll out of his surgical imaging technology.
E-Therapeutics expects to generate a “wealth of data” from clinical trials
E-Therapeutics (LON:ETX) expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates.
Inovio yields long-term immune responses from cervical cancer vaccine
Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug
OXiGENE shares rose in pre-market trading Monday
Emergent BioSolutions Acquires Rights To Lymphoma Drug
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment
YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
